1 Department of Medical Education & Research, Dubai Health Authority, Al Riyadh St - Umm Hurair 2 Dubai, UAE
The pandemic caused by Coronavirus Disease 2019 (COVID-19), also known as Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2), is believed to be one of the greatest threats to global health in the 21st century. Recent collective evidence has warranted Ruxolitinib as a potential agent in recovery. Ruxolitinib is a potent and selective inhibitor of Jack kinase (JAK) 1 and 2 with modest to marked selectivity against tyrosine kinase 2 and JAK3, respectively.
The review aims to outline the current evidence regarding the repurposed treatment for COVID- 19 and to give an insight into the clinical trials. There has been considerable interest in introducing existing therapeutic agents against COVID-19 to reduce the severity of illness and ease the burden on public healthcare systems.
A literature search was conducted using keywords like ‘Ruxolitinib trial’ and ‘COVID-19 Ruxolitinib’ on PubMed, Google Scholar, Science Direct, and Cochrane databases to select research papers and articles on the topic published from January to October 2020. Inclusion criteria were restricted to articles on Ruxolitinib and COVID, whereas the exclusion criteria stipulated that any study done on COVID-19 involving mixed treatment regimen with Ruxolitinib and other drugs or any studies not pertinent to the purpose of the study were omitted.
Based on the successful outcomes of various researches conducted and clinical trials performed, the use of Ruxolitinib has shown significant improvement and faster clinical recovery among COVID-19 patients of varying severity of infection, advanced age and multiple comorbidities. This review provides an overview of various such studies with their promising outcomes.
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
* Address correspondence to this author at Department of Medical Education & Research, Dubai Health Authority, Al Riyadh St - Umm Hurair 2 Dubai, UAE; Tel: 04 219 1920; E-mail: firstname.lastname@example.org
Abdullah Shehab Emirates Cardiac Society Emirates Medical Association Dubai (United Arab Emirates) Biography
Biography of Abdullah Shehab
Dr. Abdullah Shehab has 22 years of experience in Internal medicine, cardiology and interventional cardiology and medical education. Currently, he serves as the General Secretary of Emirates Cardiac Society and Vice President of Gulf Intervention Society. He is a Fellow of royal college of physicians UK, American college of physician, European society of cardiology, American college of cardiology, American society of cardiac intervention and fellow of the American heart association. Professor Shehab is the Chief Editor of Emirates Medical Journal and also serves as Editor in many other regional and international journals. Dr. Shehab has published 149 paper in Medline. His research interest includes: Heart failure, Coronary artery disease, Dyslipidaemia, Hypertension, Arrhythmias, Cardiac intervention, Cardiac imaging, Screening for cardiac disease in sport players, cardiovascular disease in pregnancy.